Author:
Lu Mei,Rupp Loralee B.,Melkonian Christina,Trudeau Sheri,Daida Yihe G.,Schmidt Mark A.,Gordon Stuart C.
Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. Lampertico P, Carrion JA, Curry M, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis. J Hepatol. 2020;72(6):1112–21.
2. US Food and Drug Administration. Mavret Summary Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209394Orig1s000SumR.pdf. Accessed 1 May 2023.
3. US Food and Drug Administration. Mavret: Label for New Patient Population. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209394s006lbl.pdf. Accessed May 1, 2023.
4. Brown RS Jr, Buti M, Rodrigues L, et al. Glecaprevir/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1–6 and compensated cirrhosis: the EXPEDITION-8 trial. J Hepatol. 2020;72(3):441–9.
5. US Food and Drug Administration. Mavyret Labeling Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209394s010lbl.pdf. Published 2020. Accessed 2023.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献